Washington University School of Medicine in St. Louis announced that the U.S. FDA granted Breakthrough Therapy Designation to a CAR-T cell treatment targeting uPAR for solid tumors. The therapy was licensed to Wugen, a biotech startup rooted in the Cortex Innovation District. The designation supports an accelerated regulatory development pathway intended to speed timelines for therapies showing early clinical evidence of meaningful benefit. Breakthrough status can also bring more intensive FDA interaction on trial design and evidence generation. Solid-tumor CAR-T has faced persistent hurdles, including antigen selection and the hostile tumor microenvironment. A uPAR-directed strategy aims to improve tumor recognition and persistence, and the FDA action signals that early evidence met the bar for expedited attention. The move adds momentum to the cellular immunotherapy pipeline as companies seek differentiation in solid tumor targets and trial readouts that can convert early signals into regulatory submissions.